Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib

BACKGROUND: Abivertinib is a novel oral, third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that overcomes T790M‐induced resistance in non‐small cell lung cancer (NSCLC) patients. Here, we report the results of a complete and detailed clinical data of patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanping, Pan, Ruili, Zhang, Xiaotong, Si, Xiaoyan, Wang, Mengzhao, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049520/
https://www.ncbi.nlm.nih.gov/pubmed/31943845
http://dx.doi.org/10.1111/1759-7714.13302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049520/
https://www.ncbi.nlm.nih.gov/pubmed/31943845
http://dx.doi.org/10.1111/1759-7714.13302

Ejemplares similares